Provider-Mediated Communication of Genetic Testing Results to At-Risk Relatives of Cancer Patients to Improve Genetic Counseling and Testing Rates, Family HOPE Study
City of Hope Medical Center · with National Cancer Institute (NCI) · NCT05772130
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 240
- US sites recruiting
- 1
- Study start
- March 10, 2023
- Record last updated
- October 16, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This clinical trial tests whether provider-mediated communication of genetic testing results to at-risk relatives of cancer patients can help improve genetic counseling and testing rates. Approximately 15% of people with cancer have an inherited form of cancer due to changes in a gene that they have inherited from one of their parents. These changes increase a person's risk for developing cancer. Most people who have an inherited harmful change in a cancer risk gene don't know that they have it and are therefore not able to get the health care that they need. The primary reason for this problem has been a lack of genetic counseling and testing for cancer patients and patients with a strong family history of cancer. Another reason for this lack of awareness is that, when cancer runs in a family, the patient who carries the gene change usually has to communicate the genetic risk information to their family members. When this process doesn't work well, family members may not know that they need to get genetic testing and then may not get potentially life-saving care. Provider-mediated contact to discuss genetic test results may help improve rates of genetic testing among at-risk relatives of patients with a family cancer syndrome.
Being studied: Best Practice; Electronic Health Record Review; Personal Contact; Survey Administration
Conditions: Hematopoietic and Lymphoid System Neoplasm; Hereditary Malignant Neoplasm; Malignant Solid Neoplasm
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- PATIENTS: Enrolled in City of Hope (COH) institutional review board (IRB) 07047 or have been seen by COH Genetics for genetic testing
- PATIENTS: Have an pathogenic/ likely pathogenic germline variant
- PATIENTS: Fluent in English
- PATIENTS: Age >= 18 years
- PATIENTS: Willing to provide contact information for eligible first-degree relatives
- PATIENTS: >= 2 first-degree relatives that are eligible for genetic testing and reside in the United States of America
- FIRST-DEGREE RELATIVES: Proband is a COH patient and has consented to this study
- FIRST-DEGREE RELATIVES: First-degree relative of proband
- FIRST-DEGREE RELATIVES: Resides within the United States
- FIRST-DEGREE RELATIVES: Has not undergone genetic testing for the known familial variant
- FIRST-DEGREE RELATIVES: Are fluent in English
- FIRST-DEGREE RELATIVES: Age >= 18 years
Exclusion Criteria
- PATIENTS: Unable to provide informed consent
- PATIENTS: =\< 2 at-risk first-degree relatives who are eligible for genetic testing and/or reside within the United States
- PATIENTS: Unwilling to provide contact information for family members
- FIRST-DEGREE RELATIVES: Unable or unwilling to provide informed consent
- FIRST-DEGREE RELATIVES: Have undergone genetic testing for the known familial variant
- FIRST-DEGREE RELATIVES: Resides outside of the United States
Recruiting US locations
City of Hope Medical Center
Duarte, CA 91010
Site contact: Stacy W. Gray · 626-218-8662 · stagray@coh.org
Similar studies in California
All healthy volunteers studies in California →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
AstraZeneca
- Location
- Glendale, CA + 1 other US site
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
AstraZeneca
- Location
- Rialto, CA + 1 other US site
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
Pfizer
- Location
- Lake Forest, CA + 3 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
Phase 1 Study of SBS-147 in Healthy Adults
Sparian Biosciences, Inc
- Location
- Cypress, CA
- Eligibility basics
- Ages 18–55